Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system

Cancer related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: A real-world analysis using the FDA adverse event reporting system

Saved in:

Bibliographic Details
Main Authors:	Bowen Wang, Zheyun Song, Shan Lan, Xiubi Chen, Xida Yan, Xue-Feng Jiao
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2025-01-01
Series:	PLoS ONE
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12342331/?tool=EBI
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Neurological adverse events associated with baclofen: a pharmacovigilance study based on FDA adverse event reporting system
by: Yunhan Zhao, et al.
Published: (2025-05-01)

Adverse events of pexidartinib for the treatment of TGCT: a real-world disproportionality analysis using FDA Adverse Event Reporting System database
by: Yu Lin, et al.
Published: (2025-08-01)

Safety assessment of laronidase: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS)
by: Zhuomiao Lin, et al.
Published: (2025-08-01)

Descriptive Analysis of Reported Adverse Events Associated with Vitiligo Medications Using FDA Adverse Event Reporting System (FAERS) Databases 2013–2023
by: Saleh F. Alqifari, et al.
Published: (2025-07-01)

A disproportionality analysis of FDA adverse event reporting system (FAERS) events for methimazole and propylthiouracil
by: Yun Li, et al.
Published: (2025-01-01)

Gastrointestinal adverse events associated with Lenvatinib versus Lenvatinib plus Pembrolizumab: A pharmacovigilance study in FDA adverse event reporting system
by: Chufeng Ding, et al.
Published: (2025-04-01)

Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
by: Lele Ge, et al.
Published: (2025-05-01)

Assessment of drug induced hyperuricemia and gout risk using the FDA adverse event reporting system
by: Guihao Zheng, et al.
Published: (2025-07-01)

Adverse events associated with Implantable Collamer Lens: insights from the FDA MAUDE database
by: Qing Chen, et al.
Published: (2025-07-01)

Osimertinib-related myotoxicity: a disproportionality analysis of the FDA adverse event reporting system
by: Yaqian Tan, et al.
Published: (2025-08-01)

Tirzepatide safety in type 2 diabetes: a disproportionality analysis of adverse events using the FDA FAERS database
by: Zhenpo Zhang, et al.
Published: (2025-07-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS)
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

Real-world safety assessment of Ixekizumab based on the FDA Adverse Event Reporting System (FAERS).
by: Yuzhe Cheng, et al.
Published: (2025-01-01)

A pharmacovigilance study of vortioxetine based on data from the FDA adverse event reporting system
by: Miao Liu, et al.
Published: (2025-08-01)

A real-world data analysis of montelukast in FDA Adverse Event Reporting System (FAERS) database
by: Hesen Huang, et al.
Published: (2025-07-01)

Cardiac Adverse Events in Patients Receiving Immune Checkpoint Inhibitors in the Adjuvant Setting: An FDA Pooled Analysis
by: Asma Dilawari, et al.
Published: (2025-05-01)

The real-world safety of Nivolumab: a pharmacovigilance analysis based on the FDA adverse event reporting system
by: Yutong Wu, et al.
Published: (2025-05-01)

Drug-induced pulmonary edema: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS)
by: Zilan Zhong, et al.
Published: (2025-08-01)

Post-marketing safety concerns with pirfenidone and nintedanib: an analysis of individual case safety reports from the FDA adverse event reporting system database and the Japanese adverse drug event report databases
by: Tao Wang, et al.
Published: (2025-04-01)

An investigation of drug-induced mental disorders in the children and adolescents population utilizing the FDA adverse event reporting system
by: Linlin Tang, et al.
Published: (2025-07-01)

Drug-induced herpes zoster: a pharmacovigilance analysis of FDA adverse event reports from 2004 to 2024
by: Jiali Xia, et al.
Published: (2025-03-01)

Current Physician's Perception of Proton Pump Inhibitor-related Adverse Effects
by: Cheol Woong Choi
Published: (2021-03-01)

Musculoskeletal adverse events reported post-hepatitis B vaccination in the vaccine adverse event reporting system
by: Yiqing Sun, et al.
Published: (2025-05-01)

Pharmacovigilance study of drug-induced eye movement disorder based on FDA adverse event reports from 2004 to 2024
by: Si-Yuan Hong, et al.
Published: (2025-07-01)

Cardiotoxicity Assessment of EGFR Tyrosine Kinase Inhibitors Using Human iPS Cell‐Derived Cardiomyocytes and FDA Adverse Events Reporting System
by: Shota Yanagida, et al.
Published: (2025-08-01)

What to do in the event of an adverse anaesthetic event or medical error
by: Jenny Thomas
Published: (2014-05-01)

Neurologic adverse events of cancer immunotherapy
by: Marcelo Houat de Brito
Published: (2022-08-01)

Pharmacovigilance study on the reporting frequency of atrial fibrillation with immune checkpoint inhibitors: insights from FDA Adverse Event Reporting System
by: Nunzia Balzano, et al.
Published: (2025-04-01)

An integrated approach based on FDA adverse event reporting system, network pharmacology, molecular docking, and molecular dynamics simulation analysis to study the cardiac adverse reactions and mechanism of action of osimertinib
by: Wenjuan Wang, et al.
Published: (2025-06-01)

Incidents and adverse events notified at hospital level
by: Andréia Mascarello, et al.
Published: (2021-01-01)

Incidents and adverse events notified at hospital level
by: Andréia Mascarello, et al.
Published: (2021-01-01)

Biomarkers of Adverse Cardiovascular Events in Kidney Disease
by: L. A. Kamyshnikova, et al.
Published: (2023-08-01)

Drug-induced sinusoidal obstruction syndrome: a real-world pharmacovigilance study based on the FDA Adverse Event Reporting System (FEARS)
by: Cuicui Sun, et al.
Published: (2025-07-01)

Cardiac MRI study of adverse events in patients treated with immune checkpoint inhibitors: a prospective cohort study of cardiac adverse events
by: Antonio Di Muzio, et al.
Published: (2025-03-01)

PREVENTIVE STRATEGIES OF ADVERSE EVENTS WITH POTENTIALLY DANGEROUS MEDICATIONS
by: Flavia Giron Camerini, et al.
Published: (2013-04-01)

A real-world pharmacovigilance analysis of ALK inhibitor-associated pleural and pericardial effusion using the FDA Adverse Events Reporting System (FAERS) database from 2013 to 2024.
by: Connor Frey
Published: (2025-01-01)

Dermatologic adverse events associated with epidermal growth factor receptor inhibitors: current concepts of interdisciplinary problem
by: A. S. Polonskaia, et al.
Published: (2022-02-01)

FALLING OF SENILE AGE PATIENT AS AN ADVERSE EVENT ASSOCIATED WITH THE USE OF MEDICINES: CASE REPORT
by: E. S. Ilina, et al.
Published: (2017-05-01)

Modern methods of identification of adverse events associated with medication errors
by: A. P. Pereverzev, et al.
Published: (2018-02-01)

Commentary: Musculoskeletal adverse events in dogs receiving bedinvetmab (Librela)
by: Matthew Warren Brunke, et al.
Published: (2025-07-01)